

Special Issue

TGF- β Signaling and Its Roles in Cancers

Message from the Guest Editor

It is known that cancer metabolism involves different changes at cellular level, and altered metabolic pathways have been demonstrated to be crucial in tumorigenesis and invasiveness. In cancer cells, different cytokines are involved in the development and/or progression of cancer: among these, the transforming growth factor β (TGF- β) is central in tumorigenesis, although depending on the cancer stage. Particularly, in the advanced stage of cancer, TGF- β acts as a driver of tumor progression and metastasis, via some alterations of key components involved in TGF- β signaling and some molecular events associated to the malignant progression of cancer and related to TGF- β pathway. Based on these considerations, this Special Issue will be addressed to focus and identify those targets in the TGF- β signaling pathway that could be significant for improving the preventive and therapeutic approach to cancer. Therefore, we are pleased to invite you to contribute, with original research articles and/or reviews, to this Special Issue, and for proposing further new research perspectives in the field of cancer at the molecular level.

Guest Editor

Dr. Elisabetta Aldieri

Department of Oncology, University of Torino, 10126 Torino, Italy

Deadline for manuscript submissions

closed (15 March 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/104146

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)